Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma.
OBJECTIVE
To evaluate the intraocular pressure (IOP)-lowering effect of anecortave acetate, delivered by anterior juxtascleral depot injection, in eyes with various forms of glaucoma.


METHODS
A prospective, interventional case series was carried out. Twenty-eight uncontrolled glaucoma patients received a single injection of anecortave acetate (24 to 30 mg) in 1 selected eye under topical anesthesia. Postinjection assessments were scheduled at week 1 and months 1, 2, and 3.


RESULTS
Mean ± SD age of patients was 58.2 ± 18.6 years. Twelve patients had open-angle glaucoma and 16 had angle-closure glaucoma. Uveitic/steroid-induced glaucoma was the most frequent diagnosis (11 patients, 39.2%). Mean baseline IOP was 30.7 ± 9.3 mm Hg. Mean IOP at week 1 and months 1, 2, and 3 were 21.3 ± 6.1, 19.8 ± 6.3, 20.9 ± 7.3, and 21.7 ± 6.8 mm Hg, respectively. Significant mean IOP reductions were observed at week 1 and months 1, 2, and 3 (29.3%, 33.8%, 30.1%, and 27.2%, respectively; P<0.001).


CONCLUSIONS
A single administration of anecortave acetate by anterior juxtascleral depot injection seems to result in a significant IOP reduction (compared with baseline) for at least 3 months in eyes with different types of glaucoma. No injection-related or drug-related serious adverse events were observed. Additional studies are required to better determine the efficacy, safety, and mechanism of action of this alternative treatment.
Prata
Tiago Santos
TS
Vision Institute, Federal University of São Paulo, São Paulo, Brazil.
Tavares
Ivan Maynart
IM
Mello
Paulo Augusto
PA
Tamura
Caroline
C
Lima
Verônica Castro
VC
Belfort
Rubens
R
D000368:Aged; D000869:Anterior Eye Segment; D003692:Delayed-Action Preparations; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy* / Q000503:physiopathology; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011244:Pregnadienediols / Q000008:administration & dosage*; D011446:Prospective Studies; D012590:Sclera; D014065:Tonometry, Ocular; D014792:Visual Acuity
D003692:Delayed-Action Preparations; D005938:Glucocorticoids; D011244:Pregnadienediols; C418047:anecortave acetate